While existing biomarkers such as SLFN11 expression or ATM mutation status show some association with PARP inhibitor (PARPi) response, their predictive power is limited, as they primarily reflect intrinsic tumor cell vulnerability without fully accounting for the immune landscape required for ICB synergy (4). Here, PARP1 is linked to neoplasm.